Association of Expression of Selenoprotein P in mRNA and Protein Levels with Metabolic Syndrome in Subjects with Cardiovascular Disease: Results of Selenegene Study

Background/Objectives: Selenoprotein P (SeP) is involved in transporting selenium from the liver to target tissues. As SeP confers protection against disease by reducing chronic oxidative stress, this study is aimed to assess the level of SeP in the serum of patients with metabolic syndrome (MetS) with a history of cardiovascular disease (CVD). Subjects/Methods: A cross-sectional study was conducted on 63 and 71 subjects with and without MetS in presence of documented CVD hospitals (Isfahan, Iran) Participants were recruited from December 2015 until March 2016. All demographic, anthropometric and with cardiometabolic variables (lipids, blood glucose, blood pressure) were assessed. Lifestyle related factors and personal history and familial CVD risk factors were recorded. The expression of SELP in mRNA and protein levels in the serum were measured and MetS was determined using ATPIII criteria. The level of SeP was obtained by human ELISA kit and RNA isolated by research kits and measured by real-time PCR. Binary logistic regression analysis demonstrated MetS and SeP as dependent and independent variables, respectively.Results: The prevalence of women was higher in the MetS group. There is no significant difference between mean age of subjects with MetS and without MetS. Mean of systolic and diastolic blood pressure, triglyceride, HDL-C, fasting blood sugar (FBS), BMI, and waist circumference were higher among subjects with MetS (P=0.05). Mean of SeP was lower among subjects with MetS (P< 0.04). Furthermore, the association between MetS and SeP levels remained marginally significant even after adjusting for potential confounders such as age, gender, family history, smoking status, and nutrition. SeP and WC has a significant relationship (OR, 0.995; 95% CI, 0.990 to 1.00), P<0.033). There is no significant relationship between SeP and the other components of MetS such as FBS, HDL-C, and blood pressure after controlling forconfounders.Conclusions: In conclusion, we demonstrated a significant decrease in circulating SeP levels according to MetS status in patients with documented cardiovascular disease.